Literature DB >> 30348717

CD11c-Positive Dendritic Cells in Triple-negative Breast Cancer.

Heejae Lee1,2, Hee Jin Lee1, In Hye Song3, Won Seon Bang1,2, Sun-Hee Heo1,2, Gyungyub Gong4, In Ah Park4.   

Abstract

BACKGROUND: Tumor-infiltrating lymphocytes (TILs) and tertiary lymphoid structures (TLSs) are prognostic markers in triple-negative breast cancer (TNBC). Our study analyzed the relationship between cluster of differentiation (CD)11c-positive dendritic cells (DCs) and TILs and TLSs to elucidate mechanisms of TIL influx.
MATERIALS AND METHODS: Immunohistochemical staining for CD4, CD8, and CD11c in tissue microarrays from 681 patients with TNBC was performed. The proportions of TILs and TLSs were reviewed. Two additional TNBC gene expression datasets were used.
RESULTS: CD11c expression showed a significantly positive correlation with the level of TILs and the number of CD4+ and CD8+ T-cells, as well as an abundance of TLSs. CD11C gene expression was also significantly correlated with expression of CD4, CD8, and genes related to TLSs in both datasets.
CONCLUSION: We demonstrated a strong correlation of CD11c expression, which represents DCs, with TILs and TLSs in TNBC. Further investigation is warranted to identify therapeutic modalities that facilitate recruitment and activation of DCs. Copyright
© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Breast cancer; CD11c; dendritic cell; tumor-infiltrating lymphocyte

Mesh:

Substances:

Year:  2018        PMID: 30348717      PMCID: PMC6365742          DOI: 10.21873/invivo.11415

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  34 in total

1.  Direct multiplexed measurement of gene expression with color-coded probe pairs.

Authors:  Gary K Geiss; Roger E Bumgarner; Brian Birditt; Timothy Dahl; Naeem Dowidar; Dwayne L Dunaway; H Perry Fell; Sean Ferree; Renee D George; Tammy Grogan; Jeffrey J James; Malini Maysuria; Jeffrey D Mitton; Paola Oliveri; Jennifer L Osborn; Tao Peng; Amber L Ratcliffe; Philippa J Webster; Eric H Davidson; Leroy Hood; Krassen Dimitrov
Journal:  Nat Biotechnol       Date:  2008-02-17       Impact factor: 54.908

Review 2.  Molecular characteristics of immunogenic cancer cell death.

Authors:  A Tesniere; T Panaretakis; O Kepp; L Apetoh; F Ghiringhelli; L Zitvogel; G Kroemer
Journal:  Cell Death Differ       Date:  2007-11-16       Impact factor: 15.828

3.  Density of DC-LAMP(+) mature dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor.

Authors:  Andrea Ladányi; Judit Kiss; Beáta Somlai; Katalin Gilde; Zsuzsanna Fejos; Anita Mohos; István Gaudi; József Tímár
Journal:  Cancer Immunol Immunother       Date:  2007-02-06       Impact factor: 6.968

4.  Prognostic value of tumor-infiltrating dendritic cells in colorectal cancer: role of maturation status and intratumoral localization.

Authors:  Maro H Sandel; Alisher R Dadabayev; Anand G Menon; Hans Morreau; Cornelis J M Melief; Rienk Offringa; Sjoerd H van der Burg; Connie M Janssen-van Rhijn; N Geeske Ensink; Rob A E M Tollenaar; Cornelis J H van de Velde; Peter J K Kuppen
Journal:  Clin Cancer Res       Date:  2005-04-01       Impact factor: 12.531

5.  Differential expression of CD11c by peripheral blood NK cells reflects temporal activity of multiple sclerosis.

Authors:  Toshimasa Aranami; Sachiko Miyake; Takashi Yamamura
Journal:  J Immunol       Date:  2006-10-15       Impact factor: 5.422

6.  Prognostic value of CD208-positive cell infiltration in gastric cancer.

Authors:  Sumiya Ishigami; Shinichi Ueno; Masataka Matsumoto; Hiroshi Okumura; Takaaki Arigami; Yasuto Uchikado; Tetsuro Setoyama; Hideo Arima; Ken Sasaki; Masaki Kitazono; Hiroyuki Shinchi; Yuko Kijima; Shoji Natsugoe
Journal:  Cancer Immunol Immunother       Date:  2009-09-16       Impact factor: 6.968

7.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up.

Authors:  C W Elston; I O Ellis
Journal:  Histopathology       Date:  1991-11       Impact factor: 5.087

8.  Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy.

Authors:  Lionel Apetoh; François Ghiringhelli; Antoine Tesniere; Michel Obeid; Carla Ortiz; Alfredo Criollo; Grégoire Mignot; M Chiara Maiuri; Evelyn Ullrich; Patrick Saulnier; Huan Yang; Sebastian Amigorena; Bernard Ryffel; Franck J Barrat; Paul Saftig; Francis Levi; Rosette Lidereau; Catherine Nogues; Jean-Paul Mira; Agnès Chompret; Virginie Joulin; Françoise Clavel-Chapelon; Jean Bourhis; Fabrice André; Suzette Delaloge; Thomas Tursz; Guido Kroemer; Laurence Zitvogel
Journal:  Nat Med       Date:  2007-08-19       Impact factor: 53.440

9.  Co-expression of nuclear and cytoplasmic HMGB1 is inversely associated with infiltration of CD45RO+ T cells and prognosis in patients with stage IIIB colon cancer.

Authors:  Rui-Qing Peng; Xiao-Jun Wu; Ya Ding; Chun-Yan Li; Xing-Juan Yu; Xing Zhang; Zhi-Zhong Pan; De-Sen Wan; Li-Ming Zheng; Yi-Xin Zeng; Xiao-Shi Zhang
Journal:  BMC Cancer       Date:  2010-09-16       Impact factor: 4.430

10.  The beta2 integrin CD11c distinguishes a subset of cytotoxic pulmonary T cells with potent antiviral effects in vitro and in vivo.

Authors:  Marc Beyer; Hongwei Wang; Nina Peters; Sandra Doths; Cordula Koerner-Rettberg; Peter J M Openshaw; Jürgen Schwarze
Journal:  Respir Res       Date:  2005-07-12
View more
  8 in total

1.  Immunological profiles of the breast cancer microenvironment represented by tumor-infiltrating lymphocytes and PD-L1 expression.

Authors:  Toru Hanamura; Shigehisa Kitano; Hiroshi Kagamu; Makiko Yamashita; Mayako Terao; Banri Tsuda; Takuho Okamura; Nobue Kumaki; Katsuto Hozumi; Naoki Harada; Takayuki Iwamoto; Chikako Honda; Sasagu Kurozumi; Naoki Niikura
Journal:  Sci Rep       Date:  2022-05-16       Impact factor: 4.996

2.  Is the Complement Protein C1q a Pro- or Anti-tumorigenic Factor? Bioinformatics Analysis Involving Human Carcinomas.

Authors:  Alessandro Mangogna; Chiara Agostinis; Deborah Bonazza; Beatrice Belmonte; Paola Zacchi; Gabriella Zito; Andrea Romano; Fabrizio Zanconati; Giuseppe Ricci; Uday Kishore; Roberta Bulla
Journal:  Front Immunol       Date:  2019-05-03       Impact factor: 7.561

3.  Comparative Profiling of Metastatic 4T1- vs. Non-metastatic Py230-Based Mammary Tumors in an Intraductal Model for Triple-Negative Breast Cancer.

Authors:  Jonas Steenbrugge; Niels Vander Elst; Kristel Demeyere; Olivier De Wever; Niek N Sanders; Wim Van Den Broeck; Luc Dirix; Steven Van Laere; Evelyne Meyer
Journal:  Front Immunol       Date:  2019-12-17       Impact factor: 7.561

Review 4.  Immune Infiltrates in Breast Cancer: Recent Updates and Clinical Implications.

Authors:  Maria Vittoria Dieci; Federica Miglietta; Valentina Guarneri
Journal:  Cells       Date:  2021-01-23       Impact factor: 6.600

5.  A Novel Thienopyrimidine Analog, TPH104, Mediates Immunogenic Cell Death in Triple-Negative Breast Cancer Cells.

Authors:  Diwakar Bastihalli Tukaramrao; Saloni Malla; Siddharth Saraiya; Ross Allen Hanely; Aniruddha Ray; Shikha Kumari; Dayanidhi Raman; Amit K Tiwari
Journal:  Cancers (Basel)       Date:  2021-04-18       Impact factor: 6.639

6.  Photo/thermo-responsive and size-switchable nanoparticles for chemo-photothermal therapy against orthotopic breast cancer.

Authors:  Ying Bi; Miao Wang; Lirong Peng; Lifo Ruan; Mengxue Zhou; Yi Hu; Jun Chen; Jimin Gao
Journal:  Nanoscale Adv       Date:  2019-12-17

Review 7.  Crosstalk between Tumor-Infiltrating Immune Cells and Cancer-Associated Fibroblasts in Tumor Growth and Immunosuppression of Breast Cancer.

Authors:  Jarupa Soongsathitanon; Pranisa Jamjuntra; Nuttavut Sumransub; Supaporn Yangngam; Marjorie De la Fuente; Glauben Landskron; Peti Thuwajit; Marcela A Hermoso; Chanitra Thuwajit
Journal:  J Immunol Res       Date:  2021-07-13       Impact factor: 4.818

Review 8.  Microenvironmental regulation of tumour immunity and response to immunotherapy.

Authors:  Mark M Kockx; Mark McCleland; Hartmut Koeppen
Journal:  J Pathol       Date:  2021-05-19       Impact factor: 7.996

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.